Because the coronavirus illness 2019 (COVID-19) pandemic unfolds, laboratory providers have been recognized as key to its containment. This text outlines the laboratory organisation and administration and management interventions in Niger.
The capitol metropolis of Niger, Niamey, adopted a ‘Nationwide COVID-19 Emergency Preparedness and Response Plan’ to strengthen the preparedness of the nation for the detection of extreme acute respiratory syndrome coronavirus-2. Laboratory coaching and diagnostic capability constructing had been supported by present lively medical and analysis laboratories for extra fast and practicable responses. The Nationwide Reference Laboratory for Respiratory Viruses positioned on the Centre de Recherche Médicale et Sanitaire was designated because the reference centre for COVID-19 testing. The nationwide plan for COVID-19 testing is being steadily adopted in different areas of the nation in response to the quickly evolving COVID-19 emergency and to make sure a extra fast turn-around time.
After the decentralisation of COVID-19 testing to different areas of the nation, turn-around occasions had been decreased from 48-72 h to 12-24 h. Decreasing turn-around occasions allowed Niger to scale back the size of sufferers’ stays in hospitals and isolation amenities. Shortages in testing capability should be anticipated and addressed. In an effort to scale back threat of shortages and improve availability of reagents and consumables, Niamey diversified real-time reverse transcriptase-polymerase chain response kits for extreme acute respiratory syndrome coronavirus-2 detection.
Within the period of evidence-based medication, haematological reference intervals are important for the interpretation of information for medical decision-making, monitoring of remedy and analysis. It’s not unusual that reference intervals utilized in most African nations have been obtained from revealed scientific literature, textbooks, reagent/instrument manuals.
Design of Purposeful Nanoparticles for Intractable Illness Remedy
Protein affinity reagents are extensively used for primary analysis, diagnostics, and illness remedy. Antibodies and their fragments are often called the most typical protein affinity reagents. They particularly and strongly bind to focus on molecules and inhibit their features. Thus, antibody medication have elevated within the latest 20 years for illness remedy, similar to most cancers.
These sturdy protein-protein interactions are composed of a nexus of a number of weak interactions. Artificial polymers that bind to focus on molecules have been developed by the imitation of protein-protein interactions. These polymers present nanomolar affinity for the goal and neutralize their features; thus, they’re of serious curiosity as an economical protein affinity reagent. We now have been growing artificial polymer nanoparticles (NPs) that bind to focus on peptides and proteins by the inclusion of a number of useful monomers, similar to charged and hydrophobic monomers. On this evaluate, the main focus is on the design of artificial polymer NPs that bind to focus on molecules for illness remedy. We succeeded in neutralization of poisonous peptides and signaling proteins each in vitro and in vivo. Moreover, linear polymers had been modified on a lipid nanoparticle floor to enhance polymer biodistribution. Our latest findings ought to present helpful data for the event of abiotic protein affinity reagents.
The purpose of the examine was to judge of the results of glycerol and DMSO, belonging to the endocellular kind of cryoprotective brokers (CPAs), in addition to polyethylene glycol, dextran, sucrose, and mannitol, associated to exocellular CPAs, on proteins of the membrane-cytoskeleton complicated (MCC) of human erythrocytes on the stage previous freezing. The evaluation of protein modifications was carried out by SDS-PAGE utilizing totally different approaches when making ready samples for evaluation. Using β-mercaptoethanol within the solubilizing buffer confirmed no modifications within the MCC polypeptide profile of erythrocytes preincubated with CPAs thus suggesting good biocompatibility of the studied substances.
Using the cross-linking reagent diamide for evaluation of protein modifications didn’t reveal structural abnormalities that will end in vital modifications within the localization of -SH teams and a rise within the manufacturing of high-molecular-weight polypeptide complexes recognized by SDS-PAGE with out β-mercaptoethanol. Nonetheless, the acknowledged modifications within the electrophoretic mobility of proteins within the space of band 5 in erythrocytes incubated with CPA within the presence of diamide counsel a reorganization of the structural state of actin protofilaments, which could be attributable to alterations of actin monomers themselves or initiated by modifications of actin-binding proteins within the presence of CPAs.
Technology of Keratinocytes from Human Induced Pluripotent Stem Cells Underneath Outlined Tradition Circumstances
Differentiation of keratinocytes from human embryonic stem cells (hESCs) and human induced pluripotent stem cells (hiPSCs) has develop into an necessary instrument for wound therapeutic analysis and for learning pores and skin illnesses in situations the place affected person cells usually are not out there. A number of keratinocyte differentiation protocols utilizing hiPSC colony fragments or embryoid our bodies have been revealed with some requiring extended time for differentiation or prolonged use of reagent cocktails.
On this examine, we current a simplified technique to effectively generate massive numbers of uniformly differentiated keratinocytes in lower than Four weeks from singularized hiPSCs with differentiation components, retinoic acid and bone morphogenetic protein 4 (BMP4).
Low seeding density of singularized iPSCs ends in keratinocyte cultures with minimal cell dying throughout differentiation and as much as 96% homogeneity for keratin 14-positive cells and low share of keratinocyte maturation markers, akin to early passage major keratinocytes. hiPSC-derived keratinocytes stay in a proliferative state, could be maintained for extended durations of time, and could be terminally differentiated underneath excessive calcium circumstances in the identical means as major human keratinocytes.
Rat PlGF |
|
MBS691603-5x0002mg |
MyBiosource |
5x0.002mg |
EUR 890 |
Anti-Human PGF/PlGF/PLGF Nanobody |
|
MBS1568114-01mg |
MyBiosource |
0.1mg |
EUR 405 |
Anti-Human PGF/PlGF/PLGF Nanobody |
|
MBS1568114-5x01mg |
MyBiosource |
5x0.1mg |
EUR 1520 |
Recombinant Rat PLGF |
|
MBS7610678-005mg |
MyBiosource |
0.05mg |
EUR 345 |
Recombinant Rat PLGF |
|
MBS7610678-02mg |
MyBiosource |
0.2mg |
EUR 635 |
Recombinant Rat PLGF |
|
MBS7610678-1mg |
MyBiosource |
1mg |
EUR 1800 |
Recombinant Rat PLGF |
|
MBS7610678-5x1mg |
MyBiosource |
5x1mg |
EUR 6955 |
Rat PLGF ELISA Kit |
|
ERP0025 |
Abclonal |
96Tests |
EUR 625.2 |
RABBIT ANTI HUMAN PLGF |
|
MBS222860-01mg |
MyBiosource |
0.1mg |
EUR 660 |
RABBIT ANTI HUMAN PLGF |
|
MBS222860-5x01mg |
MyBiosource |
5x0.1mg |
EUR 2795 |
Anti-Human PlGF Antibody |
|
101-M03 |
ReliaTech |
100 µg |
EUR 378 |
|
Description: Placenta growth factor (PlGF) is a member of the PDGF/VEGF family of growth factors that share a conserved pattern of eight cysteines. Alternate splicing results in at least three human mature PlGF forms containing 131 (PlGF1), 152 (PlGF2), and 203 (PlGF3) amino acids (aa) respectively. Only PlGF2 contains a highly basic heparinbinding 21 aa insert at the C-terminus. In the mouse, only one P lGF that is the equivalent of human PlGF2 has been identified. Human PlGF1 shares 56%, 55%, 74% and 95% aa identity with the appropriate isoform of mouse, rat, canine and equine PlGF. PlGF is mainly found as variably glycosylated, secreted, 55 - 60 kDa disulfide linked homodimers. Mammalian cells expressing PlGF include villous trophoblasts, decidual cells, erythroblasts, keratinocytes and some endothelial cells. Circulating PlGF increases during pregnancy, reaching a peak in mid-gestation; this increase is attenuated in preeclampsia. However, deletion of PlGF in the mouse does not affect development or reproduction. Postnatally, mice lacking PlGF show impaired angiogenesis in response to ischemia. PlGF binds and signals through VEGF R1/Flt1, but not VEGF R2/Flk-1/KDR, while VEGF binds both but signals only through the angiogenic receptor, VEGF R2. PlGF and VEGF therefore compete for binding to VEGF R1, allowing high PlGF to discourage VEGF/VEGF R1 binding and promote VEGF/VEGF R2mediated angiogenesis. However, PlGF (especially PlGF1) and some forms of VEGF can form dimers that decrease the angiogenic effect of VEGF on VEGF R2. PlGF2, but not PLGF-1, shows heparindependent binding of neuropilin (Npn)-1 and Npn2. PlGF induces monocyte activation, migration, and production of inflammatory cytokines and VEGF. These activities facilitate wound and bone fracture healing, but also contribute to inflammation in active sickle cell disease and atherosclerosis. |
Anti-Human PlGF Antibody |
|
101-M67 |
ReliaTech |
100 µg |
EUR 189 |
|
Description: Placenta growth factor (PlGF) is a member of the PDGF/VEGF family of growth factors that share a conserved pattern of eight cysteines. Alternate splicing results in at least three human mature PlGF forms containing 131 (PlGF1), 152 (PlGF2), and 203 (PlGF3) amino acids (aa) respectively. Only PlGF2 contains a highly basic heparinbinding 21 aa insert at the C-terminus. In the mouse, only one P lGF that is the equivalent of human PlGF2 has been identified. Human PlGF1 shares 56%, 55%, 74% and 95% aa identity with the appropriate isoform of mouse, rat, canine and equine PlGF. PlGF is mainly found as variably glycosylated, secreted, 55 - 60 kDa disulfide linked homodimers. Mammalian cells expressing PlGF include villous trophoblasts, decidual cells, erythroblasts, keratinocytes and some endothelial cells. Circulating PlGF increases during pregnancy, reaching a peak in mid-gestation; this increase is attenuated in preeclampsia. However, deletion of PlGF in the mouse does not affect development or reproduction. Postnatally, mice lacking PlGF show impaired angiogenesis in response to ischemia. PlGF binds and signals through VEGF R1/Flt1, but not VEGF R2/Flk-1/KDR, while VEGF binds both but signals only through the angiogenic receptor, VEGF R2. PlGF and VEGF therefore compete for binding to VEGF R1, allowing high PlGF to discourage VEGF/VEGF R1 binding and promote VEGF/VEGF R2mediated angiogenesis. However, PlGF (especially PlGF1) and some forms of VEGF can form dimers that decrease the angiogenic effect of VEGF on VEGF R2. PlGF2, but not PLGF-1, shows heparindependent binding of neuropilin (Npn)-1 and Npn2. PlGF induces monocyte activation, migration, and production of inflammatory cytokines and VEGF. These activities facilitate wound and bone fracture healing, but also contribute to inflammation in active sickle cell disease and atherosclerosis. |
Anti-Human PlGF Antibody |
|
101-M69 |
ReliaTech |
100 µg |
EUR 189 |
|
Description: Placenta growth factor (PlGF) is a member of the PDGF/VEGF family of growth factors that share a conserved pattern of eight cysteines. Alternate splicing results in at least three human mature PlGF forms containing 131 (PlGF1), 152 (PlGF2), and 203 (PlGF3) amino acids (aa) respectively. Only PlGF2 contains a highly basic heparinbinding 21 aa insert at the C-terminus. In the mouse, only one P lGF that is the equivalent of human PlGF2 has been identified. Human PlGF1 shares 56%, 55%, 74% and 95% aa identity with the appropriate isoform of mouse, rat, canine and equine PlGF. PlGF is mainly found as variably glycosylated, secreted, 55 - 60 kDa disulfide linked homodimers. Mammalian cells expressing PlGF include villous trophoblasts, decidual cells, erythroblasts, keratinocytes and some endothelial cells. Circulating PlGF increases during pregnancy, reaching a peak in mid-gestation; this increase is attenuated in preeclampsia. However, deletion of PlGF in the mouse does not affect development or reproduction. Postnatally, mice lacking PlGF show impaired angiogenesis in response to ischemia. PlGF binds and signals through VEGF R1/Flt1, but not VEGF R2/Flk-1/KDR, while VEGF binds both but signals only through the angiogenic receptor, VEGF R2. PlGF and VEGF therefore compete for binding to VEGF R1, allowing high PlGF to discourage VEGF/VEGF R1 binding and promote VEGF/VEGF R2mediated angiogenesis. However, PlGF (especially PlGF1) and some forms of VEGF can form dimers that decrease the angiogenic effect of VEGF on VEGF R2. PlGF2, but not PLGF-1, shows heparindependent binding of neuropilin (Npn)-1 and Npn2. PlGF induces monocyte activation, migration, and production of inflammatory cytokines and VEGF. These activities facilitate wound and bone fracture healing, but also contribute to inflammation in active sickle cell disease and atherosclerosis. |
Anti-Human PlGF Antibody |
|
101-MBi67 |
ReliaTech |
50 µg |
EUR 189 |
|
Description: Placenta growth factor (PlGF) is a member of the PDGF/VEGF family of growth factors that share a conserved pattern of eight cysteines. Alternate splicing results in at least three human mature PlGF forms containing 131 (PlGF1), 152 (PlGF2), and 203 (PlGF3) amino acids (aa) respectively. Only PlGF2 contains a highly basic heparinbinding 21 aa insert at the C-terminus. In the mouse, only one P lGF that is the equivalent of human PlGF2 has been identified. Human PlGF1 shares 56%, 55%, 74% and 95% aa identity with the appropriate isoform of mouse, rat, canine and equine PlGF. PlGF is mainly found as variably glycosylated, secreted, 55 - 60 kDa disulfide linked homodimers. Mammalian cells expressing PlGF include villous trophoblasts, decidual cells, erythroblasts, keratinocytes and some endothelial cells. Circulating PlGF increases during pregnancy, reaching a peak in mid-gestation; this increase is attenuated in preeclampsia. However, deletion of PlGF in the mouse does not affect development or reproduction. Postnatally, mice lacking PlGF show impaired angiogenesis in response to ischemia. PlGF binds and signals through VEGF R1/Flt1, but not VEGF R2/Flk-1/KDR, while VEGF binds both but signals only through the angiogenic receptor, VEGF R2. PlGF and VEGF therefore compete for binding to VEGF R1, allowing high PlGF to discourage VEGF/VEGF R1 binding and promote VEGF/VEGF R2mediated angiogenesis. However, PlGF (especially PlGF1) and some forms of VEGF can form dimers that decrease the angiogenic effect of VEGF on VEGF R2. PlGF2, but not PLGF-1, shows heparindependent binding of neuropilin (Npn)-1 and Npn2. PlGF induces monocyte activation, migration, and production of inflammatory cytokines and VEGF. These activities facilitate wound and bone fracture healing, but also contribute to inflammation in active sickle cell disease and atherosclerosis. |
Anti-Mouse PlGF Antibody |
|
103-M03 |
ReliaTech |
100 µg |
EUR 399 |
|
Description: Placenta growth factor (PlGF) is a member of the PDGF/VEGF family of growth factors that share a conserved pattern of eight cysteines. Alternate splicing results in at least three human mature PlGF forms containing 131 (PlGF-1), 152 (PlGF-2), and 203 (PlGF-3) amino acids (aa) respectively. Only PlGF-2 contains a highly basic heparin-binding 21 aa insert at the C-terminus. In the mouse, only one P lGF that is the equivalent of human PlGF-2 has been identified. Mouse PlGF shares 60%, 92%, 62% and 59% aa identity with the appropriate isoform of human, rat, canine and equine PlGF. PlGF is mainly found as variably glycosylated, secreted, 55 - 60 kDa disulfide linked homodimers. Mammalian cells expressing PlGF include villous trophoblasts, decidual cells, erythroblasts, keratinocytes and some endothelial cells. Circulating PlGF increases during human pregnancy, reaching a peak in mid-gestation; this increase is attenuated in preeclampsia. However, deletion of PlGF in the mouse does not affect development or reproduction. Postnatally, mice lacking PlGF show impaired angiogenesis in response to ischemia. PlGF binds and signals through VEGF R1/Flt-1, but not VEGF R2/Flk-1/KDR, while VEGF binds both but signals only through the angiogenic receptor, VEGF R2. PlGF and VEGF therefore compete for binding to VEGF R1, allowing high PlGF to discourage VEGF/VEGF R1 binding and promote VEGF/VEGF R2-mediated angiogenesis. However, PlGF (especially human PlGF-1) and some forms of VEGF can form dimers that decrease the angiogenic effect of VEGF on VEGF R2. PlGF-2, like VEGF164/165, shows heparin-dependent binding of neuropilin (Npn)-1 and Npn-2 and can inhibit nerve growth cone collapse. PlGF induces monocyte activation, migration, and production of inflammatory cytokines and VEGF. These activities facilitate wound and bone fracture healing, but also contribute to inflammation in active sickle cell disease and atherosclerosis. Circulating PlGF often correlates with tumor stage and aggressiveness, and therapeutic P lGF antibodies are being investigated to inhibit tumor growth and angiogenesis. |
Anti-Mouse PlGF Antibody |
|
103-PA04AG |
ReliaTech |
50 µg |
EUR 157.5 |
|
Description: Placenta growth factor (PlGF) is a member of the vascular endothelial growth factor (VEGF) family of growth factors. PlGF and VEGF share primary structural as well as limited amino acid sequence homology with the A and B chains of PDGF. All eight cysteine residues involved in intra and interchain disulfides are conserved among these growth factors. As a result of alternative splicing, three PlGF RNAs encoding monomeric human PlGF1, PlGF2 and PlGF3 isoform precursors containing 149, 179 and 219 amino acid residues, respectively, have been described. In normal mouse tissues, only one mouse PlGF mRNA encoding the equivalent of human PlGF2 has been identified. Mouse PlGF shares 65% amino acid identity with human PlGF2. The gene for PlGF has been mapped to mouse chromosome 12 and human chromosome 14. PlGF binds with high affinity to Flt1, but not to Flk1/KDR. |
Anti-Mouse PlGF Antibody |
|
103-PA04S |
ReliaTech |
100 µg |
EUR 126 |
|
Description: Placenta growth factor (PlGF) is a member of the vascular endothelial growth factor (VEGF) family of growth factors. PlGF and VEGF share primary structural as well as limited amino acid sequence homology with the A and B chains of PDGF. All eight cysteine residues involved in intra and interchain disulfides are conserved among these growth factors. As a result of alternative splicing, three PlGF RNAs encoding monomeric human PlGF1, PlGF2 and PlGF3 isoform precursors containing 149, 179 and 219 amino acid residues, respectively, have been described. In normal mouse tissues, only one mouse PlGF mRNA encoding the equivalent of human PlGF2 has been identified. Mouse PlGF shares 65% amino acid identity with human PlGF2. The gene for PlGF has been mapped to mouse chromosome 12 and human chromosome 14. PlGF binds with high affinity to Flt1, but not to Flk1/KDR. |
Anti-Human PlGF Antibody |
|
102-P248 |
ReliaTech |
100 µg |
EUR 245.7 |
|
Description: Placenta growth factor (PlGF) is a member of the PDGF/VEGF family of growth factors that share a conserved pattern of eight cysteines. Alternate splicing results in at least three human mature PlGF forms containing 131 (PlGF1), 152 (PlGF2), and 203 (PlGF3) amino acids (aa) respectively. Only PlGF2 contains a highly basic heparinbinding 21 aa insert at the C-terminus. In the mouse, only one P lGF that is the equivalent of human PlGF2 has been identified. Human PlGF1 shares 56%, 55%, 74% and 95% aa identity with the appropriate isoform of mouse, rat, canine and equine PlGF. PlGF is mainly found as variably glycosylated, secreted, 55 - 60 kDa disulfide linked homodimers. Mammalian cells expressing PlGF include villous trophoblasts, decidual cells, erythroblasts, keratinocytes and some endothelial cells. Circulating PlGF increases during pregnancy, reaching a peak in mid-gestation; this increase is attenuated in preeclampsia. However, deletion of PlGF in the mouse does not affect development or reproduction. Postnatally, mice lacking PlGF show impaired angiogenesis in response to ischemia. PlGF binds and signals through VEGF R1/Flt1, but not VEGF R2/Flk-1/KDR, while VEGF binds both but signals only through the angiogenic receptor, VEGF R2. PlGF and VEGF therefore compete for binding to VEGF R1, allowing high PlGF to discourage VEGF/VEGF R1 binding and promote VEGF/VEGF R2mediated angiogenesis. However, PlGF (especially PlGF1) and some forms of VEGF can form dimers that decrease the angiogenic effect of VEGF on VEGF R2. PlGF2, but not PLGF-1, shows heparindependent binding of neuropilin (Npn)-1 and Npn2. PlGF induces monocyte activation, migration, and production of inflammatory cytokines and VEGF. These activities facilitate wound and bone fracture healing, but also contribute to inflammation in active sickle cell disease and atherosclerosis. |
Anti-Mouse PlGF Antibody |
|
MBS4158465-01mg |
MyBiosource |
0.1mg |
EUR 1255 |
Anti-Mouse PlGF Antibody |
|
MBS4158465-5x01mg |
MyBiosource |
5x0.1mg |
EUR 5390 |
Anti-Human PlGF Antibody |
|
MBS4158489-01mg |
MyBiosource |
0.1mg |
EUR 920 |
Anti-Human PlGF Antibody |
|
MBS4158489-5x01mg |
MyBiosource |
5x0.1mg |
EUR 3880 |
Mouse Anti-Human PlGF |
|
MBS690289-01mg |
MyBiosource |
0.1mg |
EUR 430 |
Mouse Anti-Human PlGF |
|
MBS690289-5x01mg |
MyBiosource |
5x0.1mg |
EUR 1645 |
Mouse Anti-Human PlGF |
|
MBS690834-005mg |
MyBiosource |
0.05mg |
EUR 430 |
Mouse Anti-Human PlGF |
|
MBS690834-5x005mg |
MyBiosource |
5x0.05mg |
EUR 1645 |
Mouse Anti-Human PlGF |
|
MBS691018-01mg |
MyBiosource |
0.1mg |
EUR 430 |
Mouse Anti-Human PlGF |
|
MBS691018-5x01mg |
MyBiosource |
5x0.1mg |
EUR 1645 |
Rat PlGF Recombinant Protein |
|
R20-061 |
ReliaTech |
5 µg |
EUR 136.5 |
|
Description: Placenta growth factor (PlGF) is a member of the PDGF/VEGF family of growth factors that share a conserved pattern of eight cysteines. Alternate splicing results in at least three human mature PlGF forms containing 131 (PlGF-1), 152 (PlGF-2), and 203 (PlGF-3) amino acids (aa) respectively. Only PlGF-2 contains a highly basic heparin-binding 21 aa insert at the C-terminus. In rat only one PlGF that is the equivalent of human PlGF-2 has been identified. Rat PlGF shares 60%, 92%, 62% and 59% aa identity with the appropriate isoform of human, mouse, canine and equine PlGF. PlGF is mainly found as variably glycosylated, secreted, 55 - 60 kDa disulfide linked homodimers. Mammalian cells expressing PlGF include villous trophoblasts, decidual cells, erythroblasts, keratinocytes and some endothelial cells. Circulating PlGF increases during human pregnancy, reaching a peak in mid-gestation; this increase is attenuated in preeclampsia. However, deletion of PlGF in the mouse does not affect development or reproduction. Postnatally, mice lacking PlGF show impaired angiogenesis in response to ischemia. PlGF binds and signals through VEGF R1/Flt-1, but not VEGF R2/Flk-1/KDR, while VEGF binds both but signals only through the angiogenic receptor, VEGF R2. PlGF and VEGF therefore compete for binding to VEGF R1, allowing high PlGF to discourage VEGF/VEGF R1 binding and promote VEGF/VEGF R2-mediated angiogenesis. However, PlGF (especially human PlGF-1) and some forms of VEGF can form dimers that decrease the angiogenic effect of VEGF on VEGF R2. PlGF-2, like VEGF164/165, shows heparin-dependent binding of neuropilin (Npn)-1 and Npn-2 and can inhibit nerve growth cone collapse. PlGF induces monocyte activation, migration, and production of inflammatory cytokines and VEGF. These activities facilitate wound and bone fracture healing, but also contribute to inflammation in active sickle cell disease and atherosclerosis. Circulating PlGF often correlates with tumor stage and aggressiveness, and therapeutic PlGF antibodies are being investigated to inhibit tumor growth and angiogenesis. |
Rat PlGF Recombinant Protein |
|
R20-061S |
ReliaTech |
2 µg |
EUR 73.5 |
|
Description: Placenta growth factor (PlGF) is a member of the PDGF/VEGF family of growth factors that share a conserved pattern of eight cysteines. Alternate splicing results in at least three human mature PlGF forms containing 131 (PlGF-1), 152 (PlGF-2), and 203 (PlGF-3) amino acids (aa) respectively. Only PlGF-2 contains a highly basic heparin-binding 21 aa insert at the C-terminus. In rat only one PlGF that is the equivalent of human PlGF-2 has been identified. Rat PlGF shares 60%, 92%, 62% and 59% aa identity with the appropriate isoform of human, mouse, canine and equine PlGF. PlGF is mainly found as variably glycosylated, secreted, 55 - 60 kDa disulfide linked homodimers. Mammalian cells expressing PlGF include villous trophoblasts, decidual cells, erythroblasts, keratinocytes and some endothelial cells. Circulating PlGF increases during human pregnancy, reaching a peak in mid-gestation; this increase is attenuated in preeclampsia. However, deletion of PlGF in the mouse does not affect development or reproduction. Postnatally, mice lacking PlGF show impaired angiogenesis in response to ischemia. PlGF binds and signals through VEGF R1/Flt-1, but not VEGF R2/Flk-1/KDR, while VEGF binds both but signals only through the angiogenic receptor, VEGF R2. PlGF and VEGF therefore compete for binding to VEGF R1, allowing high PlGF to discourage VEGF/VEGF R1 binding and promote VEGF/VEGF R2-mediated angiogenesis. However, PlGF (especially human PlGF-1) and some forms of VEGF can form dimers that decrease the angiogenic effect of VEGF on VEGF R2. PlGF-2, like VEGF164/165, shows heparin-dependent binding of neuropilin (Npn)-1 and Npn-2 and can inhibit nerve growth cone collapse. PlGF induces monocyte activation, migration, and production of inflammatory cytokines and VEGF. These activities facilitate wound and bone fracture healing, but also contribute to inflammation in active sickle cell disease and atherosclerosis. Circulating PlGF often correlates with tumor stage and aggressiveness, and therapeutic PlGF antibodies are being investigated to inhibit tumor growth and angiogenesis. |
Rat PlGF Recombinant Protein |
|
R20-062 |
ReliaTech |
20 µg |
EUR 313.95 |
|
Description: Placenta growth factor (PlGF) is a member of the PDGF/VEGF family of growth factors that share a conserved pattern of eight cysteines. Alternate splicing results in at least three human mature PlGF forms containing 131 (PlGF-1), 152 (PlGF-2), and 203 (PlGF-3) amino acids (aa) respectively. Only PlGF-2 contains a highly basic heparin-binding 21 aa insert at the C-terminus. In rat only one PlGF that is the equivalent of human PlGF-2 has been identified. Rat PlGF shares 60%, 92%, 62% and 59% aa identity with the appropriate isoform of human, mouse, canine and equine PlGF. PlGF is mainly found as variably glycosylated, secreted, 55 - 60 kDa disulfide linked homodimers. Mammalian cells expressing PlGF include villous trophoblasts, decidual cells, erythroblasts, keratinocytes and some endothelial cells. Circulating PlGF increases during human pregnancy, reaching a peak in mid-gestation; this increase is attenuated in preeclampsia. However, deletion of PlGF in the mouse does not affect development or reproduction. Postnatally, mice lacking PlGF show impaired angiogenesis in response to ischemia. PlGF binds and signals through VEGF R1/Flt-1, but not VEGF R2/Flk-1/KDR, while VEGF binds both but signals only through the angiogenic receptor, VEGF R2. PlGF and VEGF therefore compete for binding to VEGF R1, allowing high PlGF to discourage VEGF/VEGF R1 binding and promote VEGF/VEGF R2-mediated angiogenesis. However, PlGF (especially human PlGF-1) and some forms of VEGF can form dimers that decrease the angiogenic effect of VEGF on VEGF R2. PlGF-2, like VEGF164/165, shows heparin-dependent binding of neuropilin (Npn)-1 and Npn-2 and can inhibit nerve growth cone collapse. PlGF induces monocyte activation, migration, and production of inflammatory cytokines and VEGF. These activities facilitate wound and bone fracture healing, but also contribute to inflammation in active sickle cell disease and atherosclerosis. Circulating PlGF often correlates with tumor stage and aggressiveness, and therapeutic PlGF antibodies are being investigated to inhibit tumor growth and angiogenesis. |
Anti-Human PlGF-2 Antibody |
|
101-M65 |
ReliaTech |
100 µg |
EUR 246.75 |
|
Description: Placenta growth factor (PlGF) is a member of the PDGF/VEGF family of growth factors that share a conserved pattern of eight cysteines. Alternate splicing results in at least three human mature PlGF forms containing 131 (PlGF1), 152 (PlGF2), and 203 (PlGF3) amino acids (aa) respectively. Only PlGF2 contains a highly basic heparinbinding 21 aa insert at the C-terminus. In the mouse, only one P lGF that is the equivalent of human PlGF2 has been identified. Human PlGF1 shares 56%, 55%, 74% and 95% aa identity with the appropriate isoform of mouse, rat, canine and equine PlGF. PlGF is mainly found as variably glycosylated, secreted, 55 - 60 kDa disulfide linked homodimers. Mammalian cells expressing PlGF include villous trophoblasts, decidual cells, erythroblasts, keratinocytes and some endothelial cells. Circulating PlGF increases during pregnancy, reaching a peak in mid-gestation; this increase is attenuated in preeclampsia. However, deletion of PlGF in the mouse does not affect development or reproduction. Postnatally, mice lacking PlGF show impaired angiogenesis in response to ischemia. PlGF binds and signals through VEGF R1/Flt1, but not VEGF R2/Flk-1/KDR, while VEGF binds both but signals only through the angiogenic receptor, VEGF R2. PlGF and VEGF therefore compete for binding to VEGF R1, allowing high PlGF to discourage VEGF/VEGF R1 binding and promote VEGF/VEGF R2mediated angiogenesis. However, PlGF (especially PlGF1) and some forms of VEGF can form dimers that decrease the angiogenic effect of VEGF on VEGF R2. PlGF2, but not PLGF-1, shows heparindependent binding of neuropilin (Npn)-1 and Npn2. PlGF induces monocyte activation, migration, and production of inflammatory cytokines and VEGF. These activities facilitate wound and bone fracture healing, but also contribute to inflammation in active sickle cell disease and atherosclerosis. |
Anti-Human PlGF-2 Antibody |
|
101-M65A |
ReliaTech |
100 µg |
EUR 246.75 |
|
Description: Placenta Growth Factor-2 (PlGF-2), a 22 kDa protein consisting of 152 amino acid residues is produced as a homodimer. PlGF is a polypeptide growth factor and a member of the platelet-derived growth factor family but more related to vascular endothelial growth factor (VEGF). PlGF acts only as a weak mitogen for those cell types possessing receptors for binding (e.g. vascular endothelial cells). At least one high-affinity receptor for PlGF (FLT-1 or VEGF-R1) has been demonstrated in different primary cell types (e.g. human umbilical vein endothelial cells and monocytes). In addition to its action as a weak mitogen it is also a chemoattractant for monocytes and endothelial cells. Three different proteins are generated by differential splicing of the human PlGF gene: PlGF-1 (131aa native chain), PlGF-2 (152aa) and PlGF-3 (203aa). All 3 mitogens are secretable proteins, but PlGF-2 can bind to heparin with high affinity. PlGF is apparently a homodimer, but preparations of PlGF show some heterogeneity on SDS gels depending of the varying degrees of glycosylation. All dimeric forms possess similar biological activities. Heterodimers between VEGF and PlGF are mitogenic for endothelial cells and have strong angiogenic activity in vivo (e.g. in the CAM assay or in the cornea pocket assay). Different cells and tissues (e.g. placenta) express PlGF-1 and PlGF-2 at different rates. A much related protein of PlGF is VEGF with about 53% homology and VEGF-B with similar biological activities. |
Mouse Anti-Human PlGF-2 |
|
MBS690323-01mg |
MyBiosource |
0.1mg |
EUR 450 |
Mouse Anti-Human PlGF-2 |
|
MBS690323-5x01mg |
MyBiosource |
5x0.1mg |
EUR 1725 |
Mouse Anti-Human PlGF-2 |
|
MBS692571-01mg |
MyBiosource |
0.1mg |
EUR 450 |
Mouse Anti-Human PlGF-2 |
|
MBS692571-5x01mg |
MyBiosource |
5x0.1mg |
EUR 1725 |
PLGF(PLGF93) Antibody |
|
BNC800093-100 |
Biotium |
100uL |
EUR 238.8 |
|
Description: Primary antibody against PLGF(PLGF93), CF680 conjugate, Concentration: 0.1mg/mL |
PLGF(PLGF93) Antibody |
|
BNC800093-500 |
Biotium |
500uL |
EUR 652.8 |
|
Description: Primary antibody against PLGF(PLGF93), CF680 conjugate, Concentration: 0.1mg/mL |
PLGF(PLGF94) Antibody |
|
BNC800094-100 |
Biotium |
100uL |
EUR 238.8 |
|
Description: Primary antibody against PLGF(PLGF94), CF680 conjugate, Concentration: 0.1mg/mL |
PLGF(PLGF94) Antibody |
|
BNC800094-500 |
Biotium |
500uL |
EUR 652.8 |
|
Description: Primary antibody against PLGF(PLGF94), CF680 conjugate, Concentration: 0.1mg/mL |
PLGF(PLGF93) Antibody |
|
BNC810093-100 |
Biotium |
100uL |
EUR 238.8 |
|
Description: Primary antibody against PLGF(PLGF93), CF680R conjugate, Concentration: 0.1mg/mL |
PLGF(PLGF93) Antibody |
|
BNC810093-500 |
Biotium |
500uL |
EUR 652.8 |
|
Description: Primary antibody against PLGF(PLGF93), CF680R conjugate, Concentration: 0.1mg/mL |
PLGF(PLGF94) Antibody |
|
BNC810094-100 |
Biotium |
100uL |
EUR 238.8 |
|
Description: Primary antibody against PLGF(PLGF94), CF680R conjugate, Concentration: 0.1mg/mL |
PLGF(PLGF94) Antibody |
|
BNC810094-500 |
Biotium |
500uL |
EUR 652.8 |
|
Description: Primary antibody against PLGF(PLGF94), CF680R conjugate, Concentration: 0.1mg/mL |
PLGF(PLGF93) Antibody |
|
BNCA0093-250 |
Biotium |
250uL |
EUR 459.6 |
|
Description: Primary antibody against PLGF(PLGF93), APC conjugate, Concentration: 0.1mg/mL |
PLGF(PLGF94) Antibody |
|
BNCA0094-250 |
Biotium |
250uL |
EUR 459.6 |
|
Description: Primary antibody against PLGF(PLGF94), APC conjugate, Concentration: 0.1mg/mL |
PLGF(PLGF93) Antibody |
|
BNC610093-100 |
Biotium |
100uL |
EUR 238.8 |
|
Description: Primary antibody against PLGF(PLGF93), CF660R conjugate, Concentration: 0.1mg/mL |
PLGF(PLGF93) Antibody |
|
BNC610093-500 |
Biotium |
500uL |
EUR 652.8 |
|
Description: Primary antibody against PLGF(PLGF93), CF660R conjugate, Concentration: 0.1mg/mL |
PLGF(PLGF94) Antibody |
|
BNC610094-100 |
Biotium |
100uL |
EUR 238.8 |
|
Description: Primary antibody against PLGF(PLGF94), CF660R conjugate, Concentration: 0.1mg/mL |
PLGF(PLGF94) Antibody |
|
BNC610094-500 |
Biotium |
500uL |
EUR 652.8 |
|
Description: Primary antibody against PLGF(PLGF94), CF660R conjugate, Concentration: 0.1mg/mL |
PLGF(PLGF93) Antibody |
|
BNC700093-100 |
Biotium |
100uL |
EUR 238.8 |
|
Description: Primary antibody against PLGF(PLGF93), CF770 conjugate, Concentration: 0.1mg/mL |
PLGF(PLGF93) Antibody |
|
BNC700093-500 |
Biotium |
500uL |
EUR 652.8 |
|
Description: Primary antibody against PLGF(PLGF93), CF770 conjugate, Concentration: 0.1mg/mL |
PLGF(PLGF94) Antibody |
|
BNC700094-100 |
Biotium |
100uL |
EUR 238.8 |
|
Description: Primary antibody against PLGF(PLGF94), CF770 conjugate, Concentration: 0.1mg/mL |
PLGF(PLGF94) Antibody |
|
BNC700094-500 |
Biotium |
500uL |
EUR 652.8 |
|
Description: Primary antibody against PLGF(PLGF94), CF770 conjugate, Concentration: 0.1mg/mL |
PLGF(PLGF93) Antibody |
|
BNCH0093-100 |
Biotium |
100uL |
EUR 238.8 |
|
Description: Primary antibody against PLGF(PLGF93), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
PLGF(PLGF93) Antibody |
|
BNCH0093-500 |
Biotium |
500uL |
EUR 652.8 |
|
Description: Primary antibody against PLGF(PLGF93), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
PLGF(PLGF94) Antibody |
|
BNCH0094-100 |
Biotium |
100uL |
EUR 238.8 |
|
Description: Primary antibody against PLGF(PLGF94), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
PLGF(PLGF94) Antibody |
|
BNCH0094-500 |
Biotium |
500uL |
EUR 652.8 |
|
Description: Primary antibody against PLGF(PLGF94), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
PLGF(PLGF93) Antibody |
|
BNCP0093-250 |
Biotium |
250uL |
EUR 459.6 |
|
Description: Primary antibody against PLGF(PLGF93), PerCP conjugate, Concentration: 0.1mg/mL |
PLGF(PLGF94) Antibody |
|
BNCP0094-250 |
Biotium |
250uL |
EUR 459.6 |
|
Description: Primary antibody against PLGF(PLGF94), PerCP conjugate, Concentration: 0.1mg/mL |
PLGF(PLGF93) Antibody |
|
BNCR0093-250 |
Biotium |
250uL |
EUR 459.6 |
|
Description: Primary antibody against PLGF(PLGF93), RPE conjugate, Concentration: 0.1mg/mL |
PLGF(PLGF94) Antibody |
|
BNCR0094-250 |
Biotium |
250uL |
EUR 459.6 |
|
Description: Primary antibody against PLGF(PLGF94), RPE conjugate, Concentration: 0.1mg/mL |
PLGF(PLGF93) Antibody |
|
BNCAP0093-100 |
Biotium |
100uL |
EUR 238.8 |
|
Description: Primary antibody against PLGF(PLGF93), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
PLGF(PLGF93) Antibody |
|
BNCAP0093-500 |
Biotium |
500uL |
EUR 652.8 |
|
Description: Primary antibody against PLGF(PLGF93), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
PLGF(PLGF94) Antibody |
|
BNCAP0094-100 |
Biotium |
100uL |
EUR 238.8 |
|
Description: Primary antibody against PLGF(PLGF94), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
PLGF(PLGF94) Antibody |
|
BNCAP0094-500 |
Biotium |
500uL |
EUR 652.8 |
|
Description: Primary antibody against PLGF(PLGF94), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
PLGF(PLGF93) Antibody |
|
BNC430093-100 |
Biotium |
100uL |
EUR 238.8 |
|
Description: Primary antibody against PLGF(PLGF93), CF543 conjugate, Concentration: 0.1mg/mL |
PLGF(PLGF93) Antibody |
|
BNC430093-500 |
Biotium |
500uL |
EUR 652.8 |
|
Description: Primary antibody against PLGF(PLGF93), CF543 conjugate, Concentration: 0.1mg/mL |
PLGF(PLGF94) Antibody |
|
BNC430094-100 |
Biotium |
100uL |
EUR 238.8 |
|
Description: Primary antibody against PLGF(PLGF94), CF543 conjugate, Concentration: 0.1mg/mL |
PLGF(PLGF94) Antibody |
|
BNC430094-500 |
Biotium |
500uL |
EUR 652.8 |
|
Description: Primary antibody against PLGF(PLGF94), CF543 conjugate, Concentration: 0.1mg/mL |
PLGF(PLGF93) Antibody |
|
BNC050093-100 |
Biotium |
100uL |
EUR 238.8 |
|
Description: Primary antibody against PLGF(PLGF93), CF405M conjugate, Concentration: 0.1mg/mL |
PLGF(PLGF93) Antibody |
|
BNC050093-500 |
Biotium |
500uL |
EUR 652.8 |
|
Description: Primary antibody against PLGF(PLGF93), CF405M conjugate, Concentration: 0.1mg/mL |
PLGF(PLGF94) Antibody |
|
BNC050094-100 |
Biotium |
100uL |
EUR 238.8 |
|
Description: Primary antibody against PLGF(PLGF94), CF405M conjugate, Concentration: 0.1mg/mL |
PLGF(PLGF94) Antibody |
|
BNC050094-500 |
Biotium |
500uL |
EUR 652.8 |
|
Description: Primary antibody against PLGF(PLGF94), CF405M conjugate, Concentration: 0.1mg/mL |
PLGF(PLGF93) Antibody |
|
BNC550093-100 |
Biotium |
100uL |
EUR 238.8 |
|
Description: Primary antibody against PLGF(PLGF93), CF555 conjugate, Concentration: 0.1mg/mL |
PLGF(PLGF93) Antibody |
|
BNC550093-500 |
Biotium |
500uL |
EUR 652.8 |
|
Description: Primary antibody against PLGF(PLGF93), CF555 conjugate, Concentration: 0.1mg/mL |
PLGF(PLGF94) Antibody |
|
BNC550094-100 |
Biotium |
100uL |
EUR 238.8 |
|
Description: Primary antibody against PLGF(PLGF94), CF555 conjugate, Concentration: 0.1mg/mL |
PLGF(PLGF94) Antibody |
|
BNC550094-500 |
Biotium |
500uL |
EUR 652.8 |
|
Description: Primary antibody against PLGF(PLGF94), CF555 conjugate, Concentration: 0.1mg/mL |
Anti-Human PGF/PlGF Antibody |
|
MBS1569264-01mg |
MyBiosource |
0.1mg |
EUR 375 |
Anti-Human PGF/PlGF Antibody |
|
MBS1569264-5x01mg |
MyBiosource |
5x0.1mg |
EUR 1390 |
Anti-Human PlGF (native) Antibody |
|
102-PABi04 |
ReliaTech |
50 µg |
EUR 157.5 |
|
Description: Placenta growth factor (PlGF) is a member of the PDGF/VEGF family of growth factors that share a conserved pattern of eight cysteines. Alternate splicing results in at least three human mature PlGF forms containing 131 (PlGF1), 152 (PlGF2), and 203 (PlGF3) amino acids (aa) respectively. Only PlGF2 contains a highly basic heparinbinding 21 aa insert at the C-terminus. In the mouse, only one P lGF that is the equivalent of human PlGF2 has been identified. Human PlGF1 shares 56%, 55%, 74% and 95% aa identity with the appropriate isoform of mouse, rat, canine and equine PlGF. PlGF is mainly found as variably glycosylated, secreted, 55 - 60 kDa disulfide linked homodimers. Mammalian cells expressing PlGF include villous trophoblasts, decidual cells, erythroblasts, keratinocytes and some endothelial cells. Circulating PlGF increases during pregnancy, reaching a peak in mid-gestation; this increase is attenuated in preeclampsia. However, deletion of PlGF in the mouse does not affect development or reproduction. Postnatally, mice lacking PlGF show impaired angiogenesis in response to ischemia. PlGF binds and signals through VEGF R1/Flt1, but not VEGF R2/Flk-1/KDR, while VEGF binds both but signals only through the angiogenic receptor, VEGF R2. PlGF and VEGF therefore compete for binding to VEGF R1, allowing high PlGF to discourage VEGF/VEGF R1 binding and promote VEGF/VEGF R2mediated angiogenesis. However, PlGF (especially PlGF1) and some forms of VEGF can form dimers that decrease the angiogenic effect of VEGF on VEGF R2. PlGF2, but not PLGF-1, shows heparindependent binding of neuropilin (Npn)-1 and Npn2. PlGF induces monocyte activation, migration, and production of inflammatory cytokines and VEGF. These activities facilitate wound and bone fracture healing, but also contribute to inflammation in active sickle cell disease and atherosclerosis. |
Anti-PGF/Plgf Picoband Antibody |
|
MBS1750586-01mg |
MyBiosource |
0.1mg |
EUR 450 |
Anti-PGF/Plgf Picoband Antibody |
|
MBS1750586-5x01mg |
MyBiosource |
5x0.1mg |
EUR 1870 |
Anti-Human PlGF (Peptide) Antibody |
|
102-PA01S |
ReliaTech |
100 µg |
EUR 115.5 |
|
Description: Placenta growth factor (PlGF) is a member of the PDGF/VEGF family of growth factors that share a conserved pattern of eight cysteines. Alternate splicing results in at least three human mature PlGF forms containing 131 (PlGF1), 152 (PlGF2), and 203 (PlGF3) amino acids (aa) respectively. Only PlGF2 contains a highly basic heparinbinding 21 aa insert at the C-terminus. In the mouse, only one P lGF that is the equivalent of human PlGF2 has been identified. Human PlGF1 shares 56%, 55%, 74% and 95% aa identity with the appropriate isoform of mouse, rat, canine and equine PlGF. PlGF is mainly found as variably glycosylated, secreted, 55 - 60 kDa disulfide linked homodimers. Mammalian cells expressing PlGF include villous trophoblasts, decidual cells, erythroblasts, keratinocytes and some endothelial cells. Circulating PlGF increases during pregnancy, reaching a peak in mid-gestation; this increase is attenuated in preeclampsia. However, deletion of PlGF in the mouse does not affect development or reproduction. Postnatally, mice lacking PlGF show impaired angiogenesis in response to ischemia. PlGF binds and signals through VEGF R1/Flt1, but not VEGF R2/Flk-1/KDR, while VEGF binds both but signals only through the angiogenic receptor, VEGF R2. PlGF and VEGF therefore compete for binding to VEGF R1, allowing high PlGF to discourage VEGF/VEGF R1 binding and promote VEGF/VEGF R2mediated angiogenesis. However, PlGF (especially PlGF1) and some forms of VEGF can form dimers that decrease the angiogenic effect of VEGF on VEGF R2. PlGF2, but not PLGF-1, shows heparindependent binding of neuropilin (Npn)-1 and Npn2. PlGF induces monocyte activation, migration, and production of inflammatory cytokines and VEGF. These activities facilitate wound and bone fracture healing, but also contribute to inflammation in active sickle cell disease and atherosclerosis. |
Polyclonal Anti-PGF (PLGF) Antibody |
|
GWB-BBP088 |
GenWay Biotech |
0.1 mg |
Ask for price |
PlGF-2/PLGF/PGF Protein, Mouse |
|
UA040136 |
Starter Biotechnology Co Ltd |
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
|
- 5 µg
- 10 µg
- 50 µg
- 100 µg
- 500 µg
- 1 mg
|
PlGF-1/PLGF/PGF Protein, Human |
|
UA040142 |
Starter Biotechnology Co Ltd |
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
|
- 5 µg
- 10 µg
- 50 µg
- 100 µg
- 500 µg
- 1 mg
|
PLGF |
|
E8ET1704-99 |
EnoGene |
100ul |
EUR 275 |
|
Description: Available in various conjugation types. |
PLGF |
|
E8EM1701-88 |
EnoGene |
100ul |
EUR 275 |
|
Description: Available in various conjugation types. |
PLGF |
|
E8EM1701-90 |
EnoGene |
100ul |
EUR 275 |
|
Description: Available in various conjugation types. |
PLGF |
|
E8ER1706-88 |
EnoGene |
100ul |
EUR 275 |
|
Description: Available in various conjugation types. |
PLGF |
|
MBS438326-002mgWithBSAAzideat02mgmL |
MyBiosource |
0.02mg(WithBSA&Azideat0.2mg/mL) |
EUR 230 |
PLGF |
|
MBS438326-01mgWithBSAAzideat02mgmL |
MyBiosource |
0.1mg(WithBSA&Azideat0.2mg/mL) |
EUR 405 |
PLGF |
|
MBS438326-01mgWithoutBSAAzideat1mgmL |
MyBiosource |
0.1mg(WithoutBSA&Azideat1mg/mL) |
EUR 405 |
PLGF |
|
MBS438326-5x01mgWithBSAAzideat02mgmL |
MyBiosource |
5x0.1mg(WithBSA&Azideat0.2mg/mL) |
EUR 1725 |
PLGF |
|
MBS438326-5x01mgWithoutBSAAzideat1mgmL |
MyBiosource |
5x0.1mg(WithoutBSA&Azideat1mg/mL) |
EUR 1725 |
PLGF |
|
MBS8535142-01mLAF405L |
MyBiosource |
0.1mL(AF405L) |
EUR 565 |
PLGF |
|
MBS8535142-01mLAF405S |
MyBiosource |
0.1mL(AF405S) |
EUR 565 |
PLGF |
|
MBS8535142-01mLAF610 |
MyBiosource |
0.1mL(AF610) |
EUR 565 |
PLGF |
|
MBS8535142-01mLAF635 |
MyBiosource |
0.1mL(AF635) |
EUR 565 |
PLGF |
|
MBS8565284-01mLAF405L |
MyBiosource |
0.1mL(AF405L) |
EUR 565 |
PLGF |
|
MBS8565284-01mLAF405S |
MyBiosource |
0.1mL(AF405S) |
EUR 565 |
PLGF |
|
MBS8565284-01mLAF610 |
MyBiosource |
0.1mL(AF610) |
EUR 565 |
PLGF |
|
MBS8565284-01mLAF635 |
MyBiosource |
0.1mL(AF635) |
EUR 565 |
PLGF |
|
MBS8565552-01mLAF405L |
MyBiosource |
0.1mL(AF405L) |
EUR 565 |
PLGF |
|
MBS8565552-01mLAF405S |
MyBiosource |
0.1mL(AF405S) |
EUR 565 |
PLGF |
|
MBS8565552-01mLAF610 |
MyBiosource |
0.1mL(AF610) |
EUR 565 |
PLGF |
|
MBS8565552-01mLAF635 |
MyBiosource |
0.1mL(AF635) |
EUR 565 |
PLGF |
|
MBS8564829-01mLAF405L |
MyBiosource |
0.1mL(AF405L) |
EUR 565 |
PLGF |
|
MBS8564829-01mLAF405S |
MyBiosource |
0.1mL(AF405S) |
EUR 565 |
PLGF |
|
MBS8564829-01mLAF610 |
MyBiosource |
0.1mL(AF610) |
EUR 565 |
PLGF |
|
MBS8564829-01mLAF635 |
MyBiosource |
0.1mL(AF635) |
EUR 565 |
PLGF |
|
MBS8564831-01mLAF405L |
MyBiosource |
0.1mL(AF405L) |
EUR 565 |
PLGF |
|
MBS8564831-01mLAF405S |
MyBiosource |
0.1mL(AF405S) |
EUR 565 |
PLGF |
|
MBS8564831-01mLAF610 |
MyBiosource |
0.1mL(AF610) |
EUR 565 |
PLGF |
|
MBS8564831-01mLAF635 |
MyBiosource |
0.1mL(AF635) |
EUR 565 |
PLGF |
|
PA1066-M |
Antagene |
100μg |
EUR 290 |
|
Description: Polyclonal Antibodies Conjugated to Magnetic Beads |
PLGF |
|
PA1066-S |
Antagene |
100μg |
EUR 290 |
|
Description: Polyclonal Antibodies Conjugated to Sepharose Beads |
PlGF Antibody |
|
5743-100 |
Biovision |
each |
EUR 405.6 |
PlGF Antibody |
|
5743-30T |
Biovision |
each |
EUR 175.2 |
PLGF Antibody |
|
49602 |
SAB |
100ul |
EUR 499 |
PLGF Antibody |
|
49602-100ul |
SAB |
100ul |
EUR 399.6 |
PLGF Antibody |
|
49602-50ul |
SAB |
50ul |
EUR 286.8 |
PLGF Antibody |
|
E8RT1505 |
EnoGene |
100ul |
EUR 225 |
|
Description: Available in various conjugation types. |
PLGF Antibody |
|
MBS9436345-005mL |
MyBiosource |
0.05mL |
EUR 325 |
PLGF Antibody |
|
MBS9436345-01mL |
MyBiosource |
0.1mL |
EUR 435 |
Furthermore, coculturing hiPSC-derived fibroblasts and keratinocytes constantly shaped organotypic 3D pores and skin equivalents. Due to this fact, keratinocytes generated by this technique are a viable supply of cells for downstream functions.